The short version
11 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
AndroGel
Testosterone · TESTOSTERONE 10 mg/g · Gel · Transdermal · ASCEND Therapeutics U.S., LLC
NDC 17139-0550-30 · 30 PACKET in 1 CARTON / 5 g in 1 PACKET · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00591-2921-02) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$1.34per unit
middle half $0.8671–$1.60 · 4,322 plans · Apr 1, 2026
Est. net of rebatesⓘ
$0.8061–$1.01
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
79%of plans cover it
tier 3 · prior auth 58% · step therapy 0% · qty limit 71%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for testosterone (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,148.50 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA021015
- TE code
- AB1
- Approval date
- Feb 28, 2000
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Testosterone (Gel)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Actavis Pharma, Inc. | TESTOSTERONE 10 mg/g | Jul 15, 2026 | Sep 3, 2026 |
| Actavis Pharma, Inc. | TESTOSTERONE 16.2 mg/g | Jul 15, 2026 | Sep 3, 2026 |
| Prasco Laboratories | TESTOSTERONE 16.2 mg/g | Jul 15, 2026 | Sep 3, 2026 |
| Upsher-Smith Laboratories, LLC | TESTOSTERONE 50 mg/5g | Jul 15, 2026 | Sep 3, 2026 |
| Actavis Pharma, Inc. | TESTOSTERONE 50 mg/5g | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Inc. | TESTOSTERONE 16.2 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Encube Ethicals, Inc. | TESTOSTERONE 16.2 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Endo USA, Inc. | TESTOSTERONE 50 mg/5g | Jul 15, 2026 | Sep 2, 2026 |
| Lupin Pharmaceuticals, Inc. | TESTOSTERONE 16.2 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Northstar Rx LLC | TESTOSTERONE 20.25 mg/1.25g | Jul 15, 2026 | Sep 2, 2026 |
| Northstar Rx LLC | TESTOSTERONE 40.5 mg/2.5g | Jul 15, 2026 | Sep 2, 2026 |
| Padagis Israel Pharmaceuticals Ltd | TESTOSTERONE 40.5 mg/2.5g | Jul 15, 2026 | Sep 2, 2026 |
| Padagis Israel Pharmaceuticals Ltd | TESTOSTERONE 16.2 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Padagis Israel Pharmaceuticals Ltd | TESTOSTERONE 20.25 mg/1.25g | Jul 15, 2026 | Sep 2, 2026 |
| Prasco Laboratories | TESTOSTERONE 12.5 mg/1.25g | Jul 15, 2026 | Sep 2, 2026 |
| Prasco Laboratories | TESTOSTERONE 25 mg/2.5g | Jul 15, 2026 | Sep 2, 2026 |
| Prasco Laboratories | TESTOSTERONE 50 mg/5g | Jul 15, 2026 | Sep 2, 2026 |
| Strides Pharma Science Limited | TESTOSTERONE 50 mg/5g | Jul 15, 2026 | Sep 2, 2026 |
| Strides Pharma Science Limited | TESTOSTERONE 25 mg/2.5g | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | TESTOSTERONE 16.2 mg/g | Jul 15, 2026 | Aug 31, 2026 |
| ASCEND Therapeutics U.S., LLC | TESTOSTERONE 10 mg/g | Jul 15, 2026 | Jul 30, 2026 |
| ASCEND Therapeutics U.S., LLC | TESTOSTERONE 16.2 mg/g | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "AndroGel — NDC 17139-0550-30," retrieved September 3, 2026, https://drugdashboards.com/drug/17139055030.
Free to cite with attribution — see how the data is put together.